These studies suggest that SSTR2-related imaging tools with radiolabeled somatostatin agonists are valuable for precise-positioning tumor detection, evaluation of disease extension, differential diagnosis, and tumor monitoring even in small, asymptomatic, or rare cases. This evidence concerns the gene SSTR2 and neoplasm.